Pharma’s 2026 hit list: The White Album

The pharmaceutical industry is poised for a strong year, despite rising global fragmentation – much like the Beatles’ White Album, a masterpiece born amid internal discord

In this bundle

Healthcare

Pharma's 2026 hit list: The White Album

Pharma's 2026 White Album will tell you all you need to know about the year ahead

Healthcare

Money (That's What I Want): 2026 is the year of truth for Trump’s pharma policies

2026 is set to bring more stability for the pharmaceutical industry, which is good for business

Healthcare

Hello, Goodbye: Europe loses ground as China becomes powerhouse of innovation

US President Trump's reforms may provide Europe a golden opportunity

Healthcare

Come Together: Pharma M&A set to accelerate in 2026

2026 should be a good year for pharma M&A as a result of reduced uncertainty and the looming patent cliff

With a Little Help From My Friends: the importance of CDMOs will continue to grow

We expect strong CDMO growth in 2026, driven by geopolitical fragmentation and regional manufacturing consolidation

Penny Lane: US and Europe stay reliant on generic medicines from Asia

Western dependence on Asian generics will remain in 2026, in spite of growing national security measures